Are investors only interested in Vertex Pharmaceuticals (VRTX) because of its cystic fibrosis drug program? We’re about to find out. After the stock exchange closed Thursday, the company announced a partial clinical hold on its first hepatitis C drug candidate by the U.S. Food and Drug Administration. Evidently, patients treated with higher doses suffered from liver toxicity. To find out more about the FDA’s reasoning and what Vertex is doing, read the full article HERE.
